FDA Requests Comments on Importation of Prescription Drugs
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The FDA is asking for public comments on how it collects information related to the importation of prescription drugs. This effort is part of moves to possibly allow U.S. states or certain entities to import drugs from Canada to lower costs for consumers. People can submit their thoughts electronically or by mail until June 15, 2026.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Public comment period on drug import data collection
- Potential drug importation from Canada to reduce consumer costs
- Entities include U.S. states, Indian tribes, and certain pharmacists or distributors
Obligations
What this law requires
Public comments on the proposed information collection related to the importation of prescription drugs must be submitted electronically or by mail.
SIP Sponsors must follow regulations set forth in 21 CFR part 251 when submitting plans to implement importation of prescription drugs from Canada.
Submit comments regarding the proposed information collection must include the Docket No. FDA-2026-N-3240.
Written/paper submissions containing confidential information must include a cover note marked 'THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'
SIP Sponsors must submit two copies of proposals, one with claimed confidential information and one without, to the Dockets Management Staff.